Aureus Asset Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $839K | Buy |
5,495
+1,183
| +27% | +$181K | 0.06% | 125 |
|
|
2025
Q4 | $595K | Buy |
4,312
+499
| +13% | +$65.3K | 0.04% | 116 |
|
|
2025
Q3 | $489K | Buy |
3,813
+190
| +5% | +$23.2K | 0.03% | 130 |
|
|
2025
Q2 | $438K | Sell |
3,623
-295
| -8% | -$33.3K | 0.03% | 130 |
|
|
2025
Q1 | $437K | Hold |
3,918
| – | – | 0.03% | 132 |
|
|
2024
Q4 | $381K | Buy |
3,918
+1,989
| +103% | +$212K | 0.02% | 144 |
|
|
2024
Q3 | $222K | Buy |
+1,929
| New | +$219K | 0.01% | 191 |
|
|
2021
Q1 | – | Sell |
-3,619
| Closed | -$342K | – | 193 |
|
|
2020
Q4 | $342K | Buy |
3,619
+4
| +0.1% | +$350 | 0.03% | 145 |
|
|
2020
Q3 | $314K | Sell |
3,615
-269
| -7% | -$23.3K | 0.03% | 140 |
|
|
2020
Q2 | $339K | Buy |
3,884
+103
| +3% | +$8.89K | 0.04% | 125 |
|
|
2020
Q1 | $312K | Sell |
3,781
-113
| -3% | -$10.1K | 0.04% | 117 |
|
|
2019
Q4 | $369K | Buy |
3,894
+59
| +2% | +$5.29K | 0.04% | 130 |
|
|
2019
Q3 | $333K | Sell |
3,835
-300
| -7% | -$26.9K | 0.04% | 127 |
|
|
2019
Q2 | $378K | Sell |
4,135
-347
| -8% | -$29.4K | 0.05% | 120 |
|
|
2019
Q1 | $386K | Buy |
4,482
+6
| +0.1% | +$482 | 0.05% | 121 |
|
|
2018
Q4 | $344K | Sell |
4,476
-437
| -9% | -$34K | 0.05% | 123 |
|
|
2018
Q3 | $379K | Sell |
4,913
-931
| -16% | -$68.8K | 0.05% | 132 |
|
|
2018
Q2 | $396K | Buy |
5,844
+101
| +2% | +$6.97K | 0.05% | 130 |
|
|
2018
Q1 | $416K | Buy |
5,743
+301
| +6% | +$22.9K | 0.06% | 113 |
|
|
2017
Q4 | $409K | Buy |
5,442
+56
| +1% | +$4.22K | 0.06% | 127 |
|
|
2017
Q3 | $414K | Sell |
5,386
-289
| -5% | -$21.8K | 0.07% | 121 |
|
|
2017
Q2 | $424K | Hold |
5,675
| – | – | 0.07% | 106 |
|
|
2017
Q1 | $400K | Buy |
5,675
+1,189
| +27% | +$79.2K | 0.07% | 114 |
|
|
2016
Q4 | $293K | Buy |
4,486
+414
| +10% | +$26.9K | 0.06% | 114 |
|
|
2016
Q3 | $288K | Buy |
4,072
+1,170
| +40% | +$85.3K | 0.06% | 111 |
|
|
2016
Q2 | $215K | Buy |
+2,902
| New | +$200K | 0.05% | 123 |
|
|
2016
Q1 | – | Sell |
-3,194
| Closed | -$246K | – | 136 |
|
|
2015
Q4 | $246K | Sell |
3,194
-1,745
| -35% | -$139K | 0.06% | 116 |
|
|
2015
Q3 | $407K | Buy |
4,939
+111
| +2% | +$9.88K | 0.1% | 95 |
|
|
2015
Q2 | $425K | Buy |
4,828
+2,248
| +87% | +$206K | 0.09% | 106 |
|
|
2015
Q1 | $228K | Buy |
+2,580
| New | +$229K | 0.05% | 136 |
|
Other funds holding NVS
Aureus Asset Management's NVS Position: Q1 2026 in Review
Aureus Asset Management increased its Novartis (NVS) stake by 27% in Q1 2026, buying an estimated $181K and bringing the position to 5,495 shares worth $839K. The position accounts for 0.06% of the portfolio, ranked #125.
Aureus Asset Management first reported a position in NVS in Q1 2015 and has held it in 30 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Aureus Asset Management held 5,495 shares of Novartis worth $839K as of Q1 2026.
- Aureus Asset Management bought 1,183 Novartis shares in Q1 2026, an estimated $181K.
- Novartis made up 0.06% of Aureus Asset Management's portfolio in Q1 2026, its #125 holding.
- Aureus Asset Management first reported a position in Novartis in Q1 2015 and has held it in 30 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Aureus Asset Management's 13F filing for Q1 2026, filed 13 May 2026.